ArticleScience (New York, N.Y.)2020
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.
Open access · hybridAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 609 papers.
0numbers the graph read from it
0cells of the map it votes in
609citing papers in PubMed
21.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
609 citing papers in PubMed, 983 citations in OpenAlex.
- Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.Frontiers in immunology · 2024Trial
- Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.Nature communications · 2023Trial
- GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.Cell reports. Medicine · 2023Trial
- Pre-vaccine sentinel antibodies predict blunted vaccine responses.Cell press blue · 2026Article
- Discordant Outcomes of SARS-CoV-2 Exposure in Household Contacts.Clinical immunology communications · 2026Article
- Seroprevalence of endemic and emergent coronaviruses among SARS-COV-2 patients and healthcare workers in Abidjan, Côte d'Ivoire.BMC infectious diseases · 2026Article
- Cross-Reactive IgG Antibody Responses to SARS-CoV-2 in Older Adults Following Seasonal Coronavirus Infection in Jiangsu, China (2015-2017).Influenza and other respiratory viruses · 2026Article
- The buried S2 apex of SARS-CoV-2 spike elicits an immunodominant germline-restricted public antibody response.bioRxiv : the preprint server for biology · 2026Article
- Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses.Communications biology · 2026Article
- SARS-CoV-2 and neutralizing antibody dynamics at a remote village in Kenya before widespread COVID-19 vaccine rollout.PLOS global public health · 2026Article
- Heterogeneity of Airborne Virus Transmission in the Built Environment: A Narrative Review.Pathogens & immunity · 2026Review
- Detailed investigation of B cell populations following vaccination and infection with severe acute respiratory syndrome coronavirus-2 during pregnancy.Frontiers in immunology · 2026Article
- A narrative review of heterogeneity in SARS-CoV-2 infection outcomes and vaccine efficacy: strategizing pandemic preparedness in Africa.Frontiers in public health · 2026Review
- Cost-Effective and Time-Saving Multiplex-Beads Immunoassay Method to Detect Humoral Immune Responses Against Respiratory Infections.Journal of immunology research · 2026Article
- Development of seropositivity to SARS-CoV-2 over the course of the COVID-19 pandemic in adolescents in a longitudinal cohort study in Cebu, Philippines.PLOS global public health · 2026Article
- Article
- Prevalence, clinical characteristics and pattern of distribution of seasonal corona virus associated acute respiratory tract infections among adults and children in the Central Province of Sri Lanka from January 2020 to October 2022.BMC infectious diseases · 2025Article
- Systemic and mucosal immune signatures of protection against SARS-CoV-2 transmission in humans.Cell reports. Medicine · 2025Article
- Longitudinal study on SARS-CoV-2 antibody responses in companion animals, Chile.The veterinary quarterly · 2025Article
- Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2.The Journal of experimental medicine · 2025Article
549 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
47 authors at 6 institutions in 1 country.
Kevin W NgRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0003-1635-6768
Nikhil FaulknerRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-7148-4634
Georgina H CornishRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-1984-6677
Annachiara RosaChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-7433-6357
Ruth HarveyWorldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.
Saira HussainWorldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-0545-244X
Rachel UlfertsCell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Christopher EarlSignalling and Structural Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-9091-9955
Antoni G WrobelStructural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-6680-5587
Donald J BentonStructural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-6748-9339
Chloe RoustanStructural Biology STP, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-8439-8997
William BollandRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.
Rachael ThompsonRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.
Ana Agua-DoceFlow Cytometry STP, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-0466-7297
Philip HobsonFlow Cytometry STP, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-5117-2994
Judith HeaneyUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.
Hannah RickmanUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.ORCID 0000-0002-3502-0744
Stavroula ParaskevopoulouUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.
Catherine F HoulihanUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.ORCID 0000-0002-7539-1566
Kirsty ThomsonUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.ORCID 0000-0002-3625-776X
Emilie SanchezUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.
Gee Yen ShinUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.ORCID 0000-0002-3564-1970
Moira J SpyerUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK.ORCID 0000-0001-9149-6029
Dhira JoshiPeptide Chemistry, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-8660-2528
Nicola O'ReillyPeptide Chemistry, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-4204-6491
Philip A WalkerStructural Biology STP, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-4062-530X
Svend KjaerStructural Biology STP, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-9767-8683
Andrew RiddellFlow Cytometry STP, The Francis Crick Institute, London NW1 1AT, UK.
Catherine MoorePublic Health Wales, University Hospital of Wales, Cardiff CF14 4XW, UK.ORCID 0000-0001-8934-0930
Bethany R JebsonCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.ORCID 0000-0002-2794-8606
Meredyth WilkinsonCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.ORCID 0000-0002-7972-8066
Lucy R MarshallCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.
Elizabeth C RosserCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.ORCID 0000-0003-4800-4695
Anna RadziszewskaCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.ORCID 0000-0002-3885-3477
Hannah PeckhamCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.ORCID 0000-0002-9668-4683
Coziana CiurtinCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.ORCID 0000-0002-8911-4113
Lucy R WedderburnCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH, Great Ormond Street Hospital (GOSH), London WC1N 3JH, UK.
Rupert BealeCell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-6705-8560
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-4299-3018
Sonia GandhiNeurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Brigitta StockingerAhRimmunity Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-8781-336X
John McCauleyWorldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-4744-6347
Steve J GamblinStructural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-5331-639X
Laura E McCoyDivision of Infection and Immunity, University College London (UCL), London WC1E 6BT, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk.ORCID 0000-0001-9503-7946
Peter CherepanovChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London NW1 1AT, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk.ORCID 0000-0002-0634-538X
Eleni NastouliUniversity College London Hospitals (UCLH) NHS Trust, London NW1 2BU, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk.ORCID 0000-0002-1684-2013
George KassiotisRetroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK. george.kassiotis@crick.ac.uk e.nastouli@ucl.ac.uk peter.cherepanov@crick.ac.uk l.mccoy@ucl.ac.uk.ORCID 0000-0002-8457-2633
The Francis Crick Institute · GBUniversity College London Hospitals NHS Foundation Trust · GBArthritis UK · GBGreat Ormond Street Hospital · GBUniversity College London · GBUniversity Hospital of Wales · GB
Funding
Medical Research Council MC_PC_19082Medical Research Council MR/M004600/1Medical Research Council MR/R008698/1Versus Arthritis 21552Versus Arthritis 22203Wellcome Trust 102898/B/13/Z
Abstract
Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable using a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the immunoglobulin G (IgG) class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.
Indexed as
Immunity, HumoralAdultAgedAged, 80 and overAmino Acid SequenceAnimalsAntibodies, ViralCOVID-19Epitope MappingFemaleHEK293 CellsHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMaleAntibodies, ViralImmunoglobulin AImmunoglobulin GImmunoglobulin MSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.